 |
PDBsum entry 2ath
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Transcription
|
PDB id
|
|
|
|
2ath
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Med Chem
48:8194-8208
(2005)
|
|
PubMed id:
|
|
|
|
|
| |
|
Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities.
|
|
N.Mahindroo,
C.F.Huang,
Y.H.Peng,
C.C.Wang,
C.C.Liao,
T.W.Lien,
S.K.Chittimalla,
W.J.Huang,
C.H.Chai,
E.Prakash,
C.P.Chen,
T.A.Hsu,
C.H.Peng,
I.L.Lu,
L.H.Lee,
Y.W.Chang,
W.C.Chen,
Y.C.Chou,
C.T.Chen,
C.M.Goparaju,
Y.S.Chen,
S.J.Lan,
M.C.Yu,
X.Chen,
Y.S.Chao,
S.Y.Wu,
H.P.Hsieh.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The synthesis and structure-activity relationship studies of novel indole
derivatives as peroxisome proliferator-activated receptor (PPAR) agonists are
reported. Indole, a drug-like scaffold, was studied as a core skeleton for the
acidic head part of PPAR agonists. The structural features (acidic head,
substitution on indole, and linker) were optimized first, by keeping
benzisoxazole as the tail part, based on binding and functional activity at
PPARgamma protein. The variations in the tail part, by introducing various
heteroaromatic ring systems, were then studied. In vitro evaluation led to
identification of a novel series of indole compounds with a benzisoxazole tail
as potent PPAR agonists with the lead compound 14 (BPR1H036) displaying an
excellent pharmacokinetic profile in BALB/c mice and an efficacious glucose
lowering activity in KKA(y) mice. Structural biology studies of 14 showed that
the indole ring contributes strong hydrophobic interactions with PPARgamma and
could be an important moiety for the binding to the protein.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
B.O.Al-Najjar,
H.A.Wahab,
T.S.Tengku Muhammad,
A.C.Shu-Chien,
N.A.Ahmad Noruddin,
and
M.O.Taha
(2011).
Discovery of new nanomolar peroxisome proliferator-activated receptor γ activators via elaborate ligand-based modeling.
|
| |
Eur J Med Chem,
46,
2513-2529.
|
 |
|
|
|
|
 |
Y.Bhurruth-Alcor,
T.Røst,
M.R.Jorgensen,
C.Kontogiorgis,
J.Skorve,
R.G.Cooper,
J.M.Sheridan,
W.D.Hamilton,
J.R.Heal,
R.K.Berge,
and
A.D.Miller
(2011).
Synthesis of novel PPARα/γ dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design program protobuild.
|
| |
Org Biomol Chem,
9,
1169-1188.
|
 |
|
|
|
|
 |
S.N.Lewis,
J.Bassaganya-Riera,
and
D.R.Bevan
(2010).
Virtual Screening as a Technique for PPAR Modulator Discovery.
|
| |
PPAR Res,
2010,
861238.
|
 |
|
|
|
|
 |
T.Waku,
T.Shiraki,
T.Oyama,
K.Maebara,
R.Nakamori,
and
K.Morikawa
(2010).
The nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolites.
|
| |
EMBO J,
29,
3395-3407.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Y.H.Peng,
M.S.Coumar,
J.S.Leou,
J.S.Wu,
H.Y.Shiao,
C.H.Lin,
W.H.Lin,
T.W.Lien,
X.Chen,
J.T.Hsu,
Y.S.Chao,
C.F.Huang,
P.C.Lyu,
H.P.Hsieh,
and
S.Y.Wu
(2010).
Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists.
|
| |
ChemMedChem,
5,
1707-1716.
|
 |
|
|
|
|
 |
A.S.Felts,
B.S.Siegel,
S.M.Young,
C.W.Moth,
T.P.Lybrand,
A.J.Dannenberg,
L.J.Marnett,
and
K.Subbaramaiah
(2008).
Sulindac derivatives that activate the peroxisome proliferator-activated receptor gamma but lack cyclooxygenase inhibition.
|
| |
J Med Chem,
51,
4911-4919.
|
 |
|
|
|
|
 |
D.Chaturvedi,
S.Ray,
A.K.Srivastava,
and
R.Chander
(2008).
Omega-(2-Naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents.
|
| |
Bioorg Med Chem,
16,
2489-2498.
|
 |
|
|
|
|
 |
D.Genest,
N.Garnier,
A.Arrault,
C.Marot,
L.Morin-Allory,
and
M.Genest
(2008).
Ligand-escape pathways from the ligand-binding domain of PPARgamma receptor as probed by molecular dynamics simulations.
|
| |
Eur Biophys J,
37,
369-379.
|
 |
|
|
|
|
 |
H.Miyachi,
and
Y.Hashimoto
(2008).
Structural Development Studies of Subtype-Selective Ligands for Peroxisome Proliferator-Activated Receptors (PPARs) Based on the 3,4-Disubstituted Phenylpropanoic Acid Scaffold as a Versatile Template.
|
| |
PPAR Res,
2008,
689859.
|
 |
|
|
|
|
 |
Y.C.Chou,
E.Prakash,
C.F.Huang,
T.W.Lien,
X.Chen,
I.J.Su,
Y.S.Chao,
H.P.Hsieh,
and
J.T.Hsu
(2008).
Bioassay-guided purification and identification of PPARalpha/gamma agonists from Chlorella sorokiniana.
|
| |
Phytother Res,
22,
605-613.
|
 |
|
|
|
|
 |
Y.H.Kao,
H.P.Hsieh,
S.K.Chitlimalla,
W.Y.Pan,
C.C.Kuo,
Y.C.Tsai,
W.H.Lin,
S.E.Chuang,
and
J.Y.Chang
(2008).
A novel peroxisome proliferator-activated receptor alpha/gamma agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells.
|
| |
Anticancer Drugs,
19,
151-158.
|
 |
|
|
|
|
 |
J.B.Bruning,
M.J.Chalmers,
S.Prasad,
S.A.Busby,
T.M.Kamenecka,
Y.He,
K.W.Nettles,
and
P.R.Griffin
(2007).
Partial agonists activate PPARgamma using a helix 12 independent mechanism.
|
| |
Structure,
15,
1258-1271.
|
 |
|
PDB codes:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |